Navigation Links
InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
Date:11/5/2013

BRISBANE, Calif., Nov. 5, 2013 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 6,500,000 shares of its common stock at a price to the public of $13.00 per share in an underwritten public offering.  InterMune has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock in connection with the offering.  InterMune estimates net proceeds from the offering to be approximately $79.6 million (assuming no exercise of the underwriters' option to purchase additional shares of common stock), after deducting underwriting discounts and commissions and estimated offering expenses.  InterMune intends to use the net proceeds from the offering to fund the commercialization of Esbriet® (pirfenidone) and its ASCEND clinical trial for U.S. registration of Esbriet, to advance the company's strategic initiatives including its new Esbriet formulations, its recently launched clinical trials supporting the use of Esbriet in idiopathic pulmonary fibrosis (IPF) and in potential new indications, its expanding anti-fibrotic research program with compounds intended to address IPF and other fibrotic diseases, and for general corporate purposes.  InterMune expects to close this transaction on or about November 12, 2013, subject to satisfaction of customary closing conditions. 

Goldman, Sachs & Co. and J. P. Morgan Securities LLC are acting as joint book-running managers of the offering.  JMP Securities LLC, Leerink Swann LLC, UBS Securities LLC and Wells Fargo Securities, LLC are acting as co-managers of the offering.  The offering is being conducted by means of a prospectus supplement filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on Form S-3.  Copies of the preliminary pr
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Andrew Powell Joins InterMune As Executive Vice President And General Counsel
2. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
3. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
4. InterMune To Release First Quarter Financial Results On April 24
5. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune To Release Third Quarter Financial Results On November 7
8. InterMune To Present At JMP Securities Healthcare Conference
9. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
10. InterMune to Present at J. P. Morgan Healthcare Conference
11. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics ... company announces that the Company,s lead antibody, HuMab 5B1, ... five separate presentations during the upcoming World Molecular Imaging ... September 2-5, 2015. Researchers from the Department of ... present results on the use of MabVax,s lead antibody ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.17 billion by 2018 ... The near future will bring Biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.20 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Israel Biomedical Sensors Market - Growth, Trends ... The Israel Biomedical Sensors market is estimated ... 3.73% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Mexico Biomedical Sensors Market Report 2015-2020 2Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2
... Submission Seeks Approval of Genasense in Relapsed/Refractory Patients, ... (Nasdaq: GNTA ) announced that the Company ... to Dr. Janet Woodcock, Acting,Director of the Center ... and Drug Administration (FDA). The appeal asks that ...
... FRANCISCO, Calif., Oct. 25 Cell,Genesys, Inc. (Nasdaq: ... and chief executive officer, and Sharon E. Tetlow, senior,vice ... host a,conference call relating to the company,s third quarter ... on Thursday, November 1,2007, at 2:00 p.m. PT/ 5:00 ...
... will Include World-Renowned RNase and RNA Researchers, ... mechanics of ribonuclease (RNase) therapeutics will be the ... hosted by Alfacell,Corporation (Nasdaq: ACEL ). ... chief,executive officer, and David Sidransky, M.D., Alfacell,s scientific,advisory ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
(Date:8/31/2015)... BURNABY, Canada , August 31, 2015 ... use of biometrics technology in government digitization projects to drive ... According to a recently published TechSci Research report, " India ... India is projected to grow at ... in the market is anticipated on account of extensive use ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ... Arabia Biomedical Sensors Market - Growth, Trends & Forecasts ... The Saudi Arabia Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/28/2015)... , August 28, 2015 ... and Training Market by Assessment Type (Pen & Paper ... Brain Training, Corporate Learning, Academic Research), Vertical and Region ... Assessment and Training Market to grow from USD 2.4 ... at a Compound Annual Growth Rate (CAGR) of 25.6% ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4
... RELEASE "Snow flea antifreeze protein" could help ... Society Scientists in Illinois and Pennsylvania are ... protein that enables billions of Canadian snow fleas to ... have practical uses in extending the storage life of ...
... transplants involve the use of stem cells from another ... major concern of the potential for acute graft-versus-host disease ... by the grafted cells against the recipient, resulting in ... are no definitive markers for predicting the development of ...
... remarkable way to protect their unborn pups. Because the ... and reactivate the ovulatory cycle, pregnant mice prevent the ... Researchers from the European Molecular Biology Laboratory (EMBL) in ... ability. A surge of the chemical signal dopamine in ...
Cached Biology News:American Chemical Society's Weekly PressPac -- July 16, 2008 2American Chemical Society's Weekly PressPac -- July 16, 2008 3American Chemical Society's Weekly PressPac -- July 16, 2008 4American Chemical Society's Weekly PressPac -- July 16, 2008 5American Chemical Society's Weekly PressPac -- July 16, 2008 6American Chemical Society's Weekly PressPac -- July 16, 2008 7American Chemical Society's Weekly PressPac -- July 16, 2008 8American Chemical Society's Weekly PressPac -- July 16, 2008 9Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes 2Pregnant mice block out unwelcome admirers to protect their pups 2
... 500 g protein in 200 l SDS-PAGE Western ... lysate; Abelson transformed macrophage cells, ... control, should be stored at ... minimized, sample vial should be ...
muscle actin (HUC1-1)...
...
Rat Antibody to Kinase Suppressor Of Ras Recognises the kinase suppressor of Ras (KSR). Immunogen: Recombinant human KSR protein Specificity: human kinase supressor of Ras...
Biology Products: